title: Pretreatment PET/CT Standardized Uptake Values Play a Role in Predicting Response to Treatment and Survival in Patients with Small Cell Lung Cancer.
abstract: BACKGROUND
  We investigated the role of standardized uptake values (SUVs) of the primary tumor in small cell lung cancer (SCLC) patients.
  
  
  METHODS
  The relationship between SUV and response to treatment was investigated using receiver operating characteristic (ROC) curve analysis, and the efficient cut-off value for detecting response to treatment was determined. The effects of SUV on response to treatment and survival were investigated.
  
  
  RESULTS
  90 patients with a median age of 58 years (range 39-83 years) were included. Median follow-up was 11 months. The suitable cut-off SUV for determination of response was found to be 10 in ROC analysis. The sensitivity and specificity of this value were 85.7% (95% confidence interval (95% CI) 63-96) and 61.8% (95% CI 49-73) (area under the curve 0.783; p = 0.0001), respectively. The overall objective response rate in patients with involvement above the cut-off value was 93.3% compared to 59.1% in those with involvement below the cut-off value (p < 0.0001). In uni- and multivariate analysis, favorable effects of limited-stage disease on response to treatment were established (p < 0.05). The effect of an SUV higher than the cut-off value on progression-free survival was borderline (p = 0.085).
  
  
  CONCLUSIONS
  These data may contribute to identifying prognostic disease characteristics and response to treatment.
authors.affiliation: Kartal Dr. Lutfi Kirdar Training and Research Hospital, Istanbul, Turkey.
authors.forename: Nur Sener
authors.initials: NS
authors.lastname: Dinc
authors.forename: Kubra
authors.initials: K
authors.lastname: Aydın
authors.forename: Hatice
authors.initials: H
authors.lastname: Odabas
authors.forename: Ozlem
authors.initials: O
authors.lastname: Ercelep
authors.forename: Gulnihal
authors.initials: G
authors.lastname: Tufan
authors.forename: Mesut
authors.initials: M
authors.lastname: Seker
authors.forename: Nurgul
authors.initials: N
authors.lastname: Yasar
authors.forename: Dincer
authors.initials: D
authors.lastname: Aydin
authors.forename: Sinemis
authors.initials: S
authors.lastname: Yuksel
authors.forename: Aslihan
authors.initials: A
authors.lastname: Mert
authors.forename: Melike
authors.initials: M
authors.lastname: Ozcelik
authors.forename: Taner
authors.initials: T
authors.lastname: Korkmaz
authors.forename: Ramazan
authors.initials: R
authors.lastname: Yildiz
authors.forename: Mehmet
authors.initials: M
authors.lastname: Aliustaoglu
authors.forename: Alpaslan
authors.initials: A
authors.lastname: Mayadagli
authors.forename: Faysal
authors.initials: F
authors.lastname: Dane
authors.forename: Mahmut
authors.initials: M
authors.lastname: Gumus
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D059248:Chemoradiotherapy / Q000401:mortality*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods / Q000592:standards / Q000706:statistics & numerical data*; D015995:Prevalence; D011379:Prognosis; D012372:ROC Curve; D012016:Reference Values; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012307:Risk Factors; D012680:Sensitivity and Specificity; D055752:Small Cell Lung Carcinoma / Q000000981:diagnostic imaging* / Q000401:mortality*; D015996:Survival Rate; D016896:Treatment Outcome; D014421:Turkey / Q000453:epidemiology